Northampton General Hospital Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2009
NCT01032057
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Northampton General Hospital | Northampton General Hospital NHS Trust

Active Ingredients

Drugs in Phase 2 Trials (2)

capecitabine (xeloda) (1 trial)

gemcitabine (gemzar) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Pancreatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2